Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TaiMed Biologics's enterprise value is NT$16,223.0 Mil.
TaiMed Biologics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$25.4 Mil. Therefore, TaiMed Biologics's EV-to-EBITDA for today is 638.95.
The historical rank and industry rank for TaiMed Biologics's EV-to-EBITDA or its related term are showing as below:
ROCO:4147'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11343.39 Med: -120.65 Max: 836.84
Current: 638.95
During the past 13 years, the highest EV-to-EBITDA of TaiMed Biologics was 836.84. The lowest was -11343.39. And the median was -120.65.
ROCO:4147's EV-to-EBITDA is ranked worse than 98% of 401
companies
in the Biotechnology industry
Industry Median: 14.15
vs ROCO:4147: 638.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
TaiMed Biologics (ROCO:4147) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TaiMed Biologics's PE Ratio (TTM) for today is calculated as:
TaiMed Biologics's share price for today is NT$64.10.
TaiMed Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for TaiMed Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, TaiMed Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's EV-to-EBITDA falls into.
TaiMed Biologics's current Enterprise Value is NT$16,223.0 Mil.
TaiMed Biologics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$25.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a EV-to-EBITDA of 638.95 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TaiMed Biologics. According to the industry distribution chart, TaiMed Biologics ranks #393 out of 401 companies in the Biotechnology industry, placing it in the top 98%.
Is TaiMed Biologics' EV-to-EBITDA too high?
TaiMed Biologics' current EV-to-EBITDA is 638.95. The Biotechnology industry median EV-to-EBITDA is 14.15. TaiMed Biologics' value of 638.95 is 4415.5% above this industry median. Based on the distribution chart, TaiMed Biologics ranks #393 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TaiMed Biologics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #393 out of 401 companies for EV-to-EBITDA. This places TaiMed Biologics in the lower half of its industry. The industry median EV-to-EBITDA is 14.15. TaiMed Biologics' value of 638.95 is 4415.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.15, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiMed Biologics's current EV-to-EBITDA of 638.95 is 4415.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TaiMed Biologics. For the Biotechnology industry, the median EV-to-EBITDA is 14.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current EV-to-EBITDA is 638.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$80.31, compared to a current price of NT$64.10 — trading 20.2% below its estimated fair value. The current EV-to-EBITDA is 638.95 and 4415.5% above the Biotechnology industry median of 14.15. TaiMed Biologics' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current EV-to-EBITDA is 638.95 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$64.10 is trading 20.2% below its estimated GF Value™ of NT$80.31.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
EV-to-EBITDA: 638.95
GF Value™: NT$80.31 vs. price of NT$64.10 (20.2% below fair value)
Industry Position: 4415.5% above the Biotechnology median (#393 of 401)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
63GF Score
Get the complete analysis for ROCO:4147
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
